Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group
Holly L. Geyer(Mayo Clinic Hospital), Peihong Zhang(Tongji University), Lydia Roy(Centre Hospitalier Universitaire de Poitiers), Jean‐Jacques Kiladjian(Délégation Paris 5), Francesco Passamonti(University of Milan), Frank Stegelmann(University Hospital Ulm), Pablo Muxí(Hospital Británico), Gunnar Birgegård(Uppsala University Hospital), Jean‐Christophe Ianotto(Inserm), Xiujuan Sun(Chinese Academy of Sciences), Heike L. Pahl(University Medical Center Freiburg), Robyn M. Scherber(Blueprint Medicines (United States)), Francisco Cervantes(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Carlos Besses(Hospital Del Mar), Dolores Hernández‐Maraver(Centre Hospitalier Universitaire de Grenoble), Andreas Reiter(Heidelberg University), Thomas Lehmann(University of Basel), Deepti Radia(St Thomas' Hospital), Maria Luisa Ferrari(University of Bergamo), Harry C. Schouten, Norman Maldonado(University of Puerto Rico System), Heidi Kosiorek(Mayo Clinic in Florida), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Jan Samuelsson(Karolinska University Hospital), Peter Johansson(Linköping University), Konstanze Döhner(University Hospital Ulm), Björn Andréasson(NU Hospital Group), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Federico Sackmann(Centre Hospitalier Universitaire de Grenoble), Zhijian Xiao(Chinese Academy of Medical Sciences & Peking Union Medical College), Stefanie Slot(Amsterdam UMC Location Vrije Universiteit Amsterdam), Tiziano Barbui(University of Bergamo), Gabriel Étienne(Institut Bergonié), Karin Bonatz(Centre Hospitalier Universitaire de Grenoble), Chiara Paoli(University of Genoa), Dana Ranta(Centre Hospitalier Régional et Universitaire de Nancy), Sonja Zweegman(Vrije Universiteit Amsterdam), Giovanni Barosi(Policlinico San Matteo Fondazione), Amylou C. Dueck(Mayo Clinic in Arizona), Yue Zhang(Beijing YouAn Hospital), Zefeng Xu(Henan University), Junqing Xu(Shenzhen University), Peter AW te Boekhorst(Erasmus MC), Keith Cannon(Mayo Clinic in Arizona), Jean‐Yves Cahn(Université Grenoble Alpes), Françoise Boyer(Centre Hospitalier Universitaire d'Angers), Zhenya Senyak, Ana Kerguelen Fuentes(Centre Hospitalier Universitaire de Grenoble), Martin Grießhammer(Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie)
Cited by 73
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k